U.S. Cannabis Stocks

There is more public support for cannabis law reform than ever before with new polls showing more than half the country is in favor of legalizing cannabis. The Drug Policy Alliance believes cannabis should be removed from the criminal justice system and regulated like alcohol and tobacco.

Why should cannabis be legalized? First, to reduce harm. The criminalization of cannabis use disproportionately harms young people and people of color, sponsors massive levels of violence and corruption, and fails to curb youth access. Second, to create jobs. Legalizing and regulating cannabis will bring one of the nation’s largest cash crops under the rule of law. This will create jobs and economic opportunities in the formal economy instead of the illicit market. Third, to save money. Scarce law enforcement resources will be better used to ensure public safety while reducing corrections and court costs. State and local governments would acquire significant new sources of tax revenue from regulating cannabis sales. Fourth, to promote consumer safety. Cannabis product testing is becoming a standard requirement for legalized cannabis markets. This means consumers are better informed about the cannabis they use.

Just how big is the market for legal cannabis? A recent report by a leading consulting firm found legal cannabis sales jumped 17% to $5.4 billion in 2015 and they will grow by a whopping 25% this year to reach $6.7 billion in total U.S. sales. More recently, another consulting firm prediction that the legal cannabis market will see a whopping $21.8 billion in total annual sales by 2020, which by comparison, at that point, the legal marijuana market could be bigger than the National Football League, which saw roughly $12 billion of revenue last year.

We are so excited that Cannabis Stock Picks is providing you with investment research on the cannabis industry through our upcoming launch of cannabisstockpicks.com. In fact, our excitement is bubbling over so we are front running our upcoming launch with a quick review of 8 stocks. This is quite the opportune time for review considering legalizing medicinal use will be on the ballet in the United States across 23 states this year (25 already legal) and legalizing recreational use will be on the ballet in Canada next year (medicinal already legal at the federal level).

22nd Century Group, Inc. (NYSE: XXII)

//
Comment0
Breaking News: FDA wants to make cigarettes less addictive by slashing nicotine in them. For the first time, the federal government is proposing cutting the nicotine level in cigarettes so they aren’t so addictive. U.S. Food and Drug Administration chief Scott Gottlieb directed the agency’s staff Friday to develop new regulations on nicotine. The FDA has had the power since 2009 to regulate nicotine levels, but so far it hasn’t done...
Read More →

Packaging Pot Profits with Kush Bottles, Inc. (OTC: KSHB, $2.33)

//
Comment0
It’s been tough-sledding for most cannabis-related equities in 2017, with small-cap and OTC issues bearing the brunt of the negative sentiment. In fact, except for a brief momentum run in Canadian pot stocks several months ago and some spates of buying interest in high profile companies like Zynerba, Inc. (ZYNE), the entire sector has almost uniformly headed south. The ascension of the beleaguered Trump Administration’s anti-marijuana Attorney General Jeff Sessions,...
Read More →

MassRoots Inc. (OTCBB: MSRT)

//
Comment0
Breaking News: Cannabis review site MassRoots will acquire Odava for $1.75 million in an essentially all-stock transaction. Odava makes point-of-sale and inventory management software for cannabis dispensaries and growers. Key Takeaways: (i) The combination of the two companies creates one of the largest technology conglomerates in the cannabis market. A complete overview of the transaction can be found here. (ii) The deal promises to provide a vertically-oriented marketing and business...
Read More →

Massive Upside In MassRoots

//
Comment1
Company Description: Powered by more than 1 million registered users, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., effectiveness for treating ailments such back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary. Businesses can leverage MassRoots by strategically advertising to consumers based on their preferences and tendencies. Investment Conclusion: We are bullish...
Read More →

Special Quarterly Update: Outlook for the Cannabis Stocks

//
Comment1
Marijuana Stock Market Review & Outlook Canadian stocks in general got off to a positive but unspectacular start in the first quarter of 2017 as the TSX Composite Index advanced from 15,288 to 15,548 for a gain of 1.7%. The Canadian markets seemed to be riding the coattails of the rally in U.S. stocks dubbed the “Trump bump.” In the U.S. stocks got off to a strong start with the...
Read More →

22ND CENTURY GROUP, INC. (NYSEMKT: XXII)

//
Comment0
Company Overview: 22nd Century is a plant biotechnology company focused on technology, which allows the company to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The company’s primary mission in tobacco is to reduce the harm caused by smoking. The company’s primary mission in cannabis is to develop proprietary cannabis strains for important new...
Read More →

Insys Therapeutics Inc. (NASDAQ: INSY)

//
Comment0
Company Description: Insys Therapeutics aims to take the rough edges off of chemo and cancer pain. The commercial-stage drug development company is focused on treating side effects of chemotherapy, as well as therapies for pain management. Its first product is Subsys, which brings in virtually all of its revenue; it is a fast-acting oral spray version of cancer pain drug Fentanyl. Syndros (dronabinol), which was approved by the FDA in...
Read More →

Kush Bottles (OTC: KSHB)

//
Comment1
By Jon Slotnick Introduction Greetings and Happy New Year! This is the first article in our weekly series covering stocks in the burgeoning cannabis sector, one of the most rapidly growing and exciting of any industry in the publically-traded universe. Opportunities for both trading and investing profits will abound in 2017, but as with all stocks, there are inherent risks as we seek out these rewards. Our goal is to alert...
Read More →

Scotts Miracle Gro (NYSE: SMG)

//
Comment0
Investment Overview: Company Description. Scott Miracle-Grow is the undisputed leader in the $7 billion U.S. lawn and garden industry. Revenue is $3.0+ billion and growing consistently around 4-5%. Scotts Miracle-Gro, an Ohio corporation, traces its heritage back to a company founded by O.M. Scott in Marysville, Ohio in 1868. The company has become widely known for the development of quality lawn fertilizers and grass seeds that led to the creation of...
Read More →

AeroGrow International (OTCMKTS: AERO)

//
Comment0
Investment Overview: Company Description. Headquartered in Boulder, Colorado, AeroGrow is the leader in the rapidly growing indoor gardening market with a commitment to helping people successfully grow healthy, fresh food – and more – regardless of season, location, or experience. Sales are just over $20 million and the company is 80% owned by the US lawn care industry titan Scotts Miracle-Gro. Outlook. We think this one is a no-brainer. Scotts Miracle-Gro is...
Read More →

Zynerba Pharmaceuticals (NASDAQ: ZYNE)

//
Comment0
Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis, and Fragile X syndrome. The company’s ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a...
Read More →

GW Pharmaceuticals (NASDAQ: GWPH)

//
Comment0
Overview GW Pharmaceuticals is a biotechnology company pioneering the commercial use of pain medications derived from cannabis sativa. Their two flagship products, Epidiolex and Sativex, are both medications comprised of the chemical compounds extracted from cannabis plants, called cannabinoids (more specifically, cannabidiol (CBD) and tetrahydrocannabinol (THC). The company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development. GW is a world leader in...
Read More →